Evaluation of Cartilage Integrity Following Administration of Oral and Intraarticular Nifedipine in a Murine Model of Osteoarthritis.
L-type channel blockers
biomarkers
calcium
cartilage damage
meniscus
mouse
nifedipine
osteoarthritis
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
received:
18
07
2023
revised:
25
08
2023
accepted:
29
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Osteoarthritis (OA) ranks as the prevailing type of arthritis on a global scale, for which no effective treatments are currently available. Arterial hypertension is a common comorbidity in OA patients, and antihypertensive drugs, such as nifedipine (NIF), may affect the course of OA progression. The aim of this preclinical study was to determine the effect of nifedipine on healthy and OA cartilage, depending on its route of administration. In this study, we used the destabilization of medial meniscus to develop a mouse model of OA. Nifedipine was applied per os or intraarticularly (i.a.) for 8 weeks to both mice with OA and healthy animals. Serum biomarker concentrations were evaluated using the Luminex platform and alterations in the knee cartilage were graded according to OARSI histological scores and investigated immunohistochemically. Nifedipine treatment per os and i.a. exerted protective effects, as assessed by the OARSI histological scores. However, long-term nifedipine i.a. injections induced the deterioration of healthy cartilage. Lubricin, cartilage intermediate layer matrix protein (CILP), collagen type VI (COLVI), CILP, and Ki67 were upregulated by the nifedipine treatment. Serum biomarkers MMP-3, thrombospondin-4, and leptin were upregulated in the healthy groups treated with nifedipine, while only the levels of MMP-3 were significantly higher in the OA group treated with nifedipine per os compared to the untreated group. In conclusion, this study highlights the differential effects of nifedipine on cartilage integrity, depending on the route of administration and cartilage condition.
Identifiants
pubmed: 37760884
pii: biomedicines11092443
doi: 10.3390/biomedicines11092443
pmc: PMC10526042
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Structural and Social Funds through the Research Council of Lithuania
ID : No 01.2.2-LMT-K-718-02-0022
Références
Life Sci. 2020 Jul 15;253:117292
pubmed: 31927051
Osteoarthritis Cartilage. 2005 Jul;13(7):632-41
pubmed: 15896985
Annu Rev Biomed Eng. 2019 Jun 4;21:495-521
pubmed: 30969794
Redox Biol. 2022 Dec;58:102521
pubmed: 36459715
J Cell Physiol. 2010 Aug;224(2):540-8
pubmed: 20432454
J Biol Chem. 1998 Sep 4;273(36):23463-8
pubmed: 9722583
Arthritis Rheumatol. 2022 Jul;74(7):1172-1183
pubmed: 35233975
Front Med (Lausanne). 2020 Oct 21;7:572977
pubmed: 33195320
Matrix Biol. 2014 Oct;39:17-24
pubmed: 25172828
Int J Mol Sci. 2023 May 25;24(11):
pubmed: 37298174
Osteoarthritis Cartilage. 2012 Aug;20(8):846-53
pubmed: 22595228
Bioengineering (Basel). 2023 Apr 07;10(4):
pubmed: 37106641
PLoS One. 2020 Sep 29;15(9):e0239663
pubmed: 32991618
Front Endocrinol (Lausanne). 2019 Nov 08;10:756
pubmed: 31781032
Open Orthop J. 2012;6:150-9
pubmed: 22523526
Arthritis Res Ther. 2006;8(5):217
pubmed: 16879738
PLoS One. 2014 Mar 21;9(3):e92699
pubmed: 24658359
Int J Mol Sci. 2019 Jan 21;20(2):
pubmed: 30669608
J Mol Cell Cardiol. 2015 Oct;87:152-9
pubmed: 26254182
Exp Gerontol. 2012 May;47(5):406-9
pubmed: 22459696
Drug Metab Dispos. 2009 Mar;37(3):651-7
pubmed: 19056912
Bone Res. 2017 Jan 17;5:16044
pubmed: 28149655
Bioengineering (Basel). 2023 Mar 01;10(3):
pubmed: 36978703
Osteoarthritis Cartilage. 1999 Mar;7(2):191-202
pubmed: 10222218
Cells. 2021 Sep 28;10(10):
pubmed: 34685552
Trends Pharmacol Sci. 1990 Mar;11(3):112-5
pubmed: 2104462
Medicine (Baltimore). 2017 Aug;96(32):e7584
pubmed: 28796041
J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):121-30
pubmed: 25398848
J Biol Chem. 2011 Oct 28;286(43):37758-67
pubmed: 21880736
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5852-7
pubmed: 23530215
Osteoarthritis Cartilage. 2002 Jun;10(6):464-70
pubmed: 12056849
Sci Rep. 2022 Apr 19;12(1):6434
pubmed: 35440750
J Orthop Res. 2018 Feb;36(2):594-604
pubmed: 29080354
Nat Rev Rheumatol. 2021 Sep;17(9):533-549
pubmed: 34316066
Osteoarthritis Cartilage. 2021 Apr;29(4):536-546
pubmed: 33561541
Best Pract Res Clin Rheumatol. 2022 Dec;36(4):101810
pubmed: 36642619
Biomed Pharmacother. 2020 Sep;129:110452
pubmed: 32768946
Arthritis Rheumatol. 2015 May;67(5):1286-94
pubmed: 25604429
Chronic Dis Transl Med. 2022 Mar 29;8(1):41-50
pubmed: 35620158
J Orthop Surg Res. 2015 Jan 09;10:1
pubmed: 25573427
Int J Mol Sci. 2021 Sep 07;22(18):
pubmed: 34575847
Front Immunol. 2021 Jan 29;11:622468
pubmed: 33584724
Biomedicines. 2023 Jul 08;11(7):
pubmed: 37509581
Front Physiol. 2021 Jul 02;12:663978
pubmed: 34276395
Channels (Austin). 2010 Nov-Dec;4(6):510-7
pubmed: 21150297
J Orthop Res. 2007 Jul;25(7):873-83
pubmed: 17343281
NPJ Regen Med. 2022 Sep 16;7(1):51
pubmed: 36114234
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S17-23
pubmed: 20864019
J Orthop Translat. 2021 Jun 12;32:12-20
pubmed: 35591938
FASEB J. 2020 May;34(5):6466-6478
pubmed: 32175635
Bone. 2021 Sep;150:115999
pubmed: 33971315
Mol Med Rep. 2015 Mar;11(3):1566-72
pubmed: 25384676
Cartilage. 2021 Dec;13(2_suppl):1501S-1512S
pubmed: 31729263
Ann Rheum Dis. 2010 Apr;69(4):761-5
pubmed: 19487215
Life (Basel). 2022 Apr 18;12(4):
pubmed: 35455094
Cell Res. 2019 Sep;29(9):739-753
pubmed: 31444469
Curr Rheumatol Rep. 2015 Jul;17(7):43
pubmed: 25980668
Eur J Cell Biol. 1994 Feb;63(1):114-21
pubmed: 8005098